124 related articles for article (PubMed ID: 35758642)
1. Targeting Protein Interaction Hotspots Using Structured and Disordered Chimeric Peptide Inhibitors.
Mayer G; Shpilt Z; Kowalski H; Tshuva EY; Friedler A
ACS Chem Biol; 2022 Jul; 17(7):1811-1823. PubMed ID: 35758642
[TBL] [Abstract][Full Text] [Related]
2. Targeting an Interaction Between Two Disordered Domains by Using a Designed Peptide.
Mayer G; Shpilt Z; Bressler S; Marcu O; Schueler-Furman O; Tshuva EY; Friedler A
Chemistry; 2020 Aug; 26(45):10240-10249. PubMed ID: 32181542
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for the conserved binding mechanism of MDM2-inhibiting peptides and anti-apoptotic Bcl-2 family proteins.
Lee MS; Ha JH; Yoon HS; Lee CK; Chi SW
Biochem Biophys Res Commun; 2014 Feb; 445(1):120-5. PubMed ID: 24491548
[TBL] [Abstract][Full Text] [Related]
4. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
[TBL] [Abstract][Full Text] [Related]
5. Functional consequences of retro-inverso isomerization of a miniature protein inhibitor of the p53-MDM2 interaction.
Li C; Zhan C; Zhao L; Chen X; Lu WY; Lu W
Bioorg Med Chem; 2013 Jul; 21(14):4045-50. PubMed ID: 23660015
[TBL] [Abstract][Full Text] [Related]
6. Binding Ensembles of
Lang L; Perez A
Molecules; 2021 Jan; 26(1):. PubMed ID: 33401765
[TBL] [Abstract][Full Text] [Related]
7. hDM2 protein-binding peptides screened from stapled α-helical peptide phage display libraries with different types of staple linkers.
Anananuchatkul T; Tsutsumi H; Miki T; Mihara H
Bioorg Med Chem Lett; 2020 Dec; 30(23):127605. PubMed ID: 33038548
[TBL] [Abstract][Full Text] [Related]
8. Angler Peptides: Macrocyclic Conjugates Inhibit p53:MDM2/X Interactions and Activate Apoptosis in Cancer Cells.
Philippe GJ; Mittermeier A; Lawrence N; Huang YH; Condon ND; Loewer A; Craik DJ; Henriques ST
ACS Chem Biol; 2021 Feb; 16(2):414-428. PubMed ID: 33533253
[TBL] [Abstract][Full Text] [Related]
9. CDK9 inhibitors reactivate p53 by downregulating iASPP.
Wu J; Liang Y; Tan Y; Tang Y; Song H; Wang Z; Li Y; Lu M
Cell Signal; 2020 Mar; 67():109508. PubMed ID: 31866490
[TBL] [Abstract][Full Text] [Related]
10. D-peptide inhibitors of the p53-MDM2 interaction for targeted molecular therapy of malignant neoplasms.
Liu M; Li C; Pazgier M; Li C; Mao Y; Lv Y; Gu B; Wei G; Yuan W; Zhan C; Lu WY; Lu W
Proc Natl Acad Sci U S A; 2010 Aug; 107(32):14321-6. PubMed ID: 20660730
[TBL] [Abstract][Full Text] [Related]
11. Flexibility vs Preorganization: Direct Comparison of Binding Kinetics for a Disordered Peptide and Its Exact Preorganized Analogues.
Saglam AS; Wang DW; Zwier MC; Chong LT
J Phys Chem B; 2017 Nov; 121(43):10046-10054. PubMed ID: 28992700
[TBL] [Abstract][Full Text] [Related]
12. High affinity interaction of the p53 peptide-analogue with human Mdm2 and Mdmx.
Czarna A; Popowicz GM; Pecak A; Wolf S; Dubin G; Holak TA
Cell Cycle; 2009 Apr; 8(8):1176-84. PubMed ID: 19305137
[TBL] [Abstract][Full Text] [Related]
13. Structure of a stapled peptide antagonist bound to nutlin-resistant Mdm2.
Chee SM; Wongsantichon J; Soo Tng Q; Robinson R; Joseph TL; Verma C; Lane DP; Brown CJ; Ghadessy FJ
PLoS One; 2014; 9(8):e104914. PubMed ID: 25115702
[TBL] [Abstract][Full Text] [Related]
14. Cell Membrane Composition Drives Selectivity and Toxicity of Designed Cyclic Helix-Loop-Helix Peptides with Cell Penetrating and Tumor Suppressor Properties.
Philippe GJ; Gaspar D; Sheng C; Huang YH; Benfield AH; Condon ND; Weidmann J; Lawrence N; Löwer A; Castanho MARB; Craik DJ; Troeira Henriques S
ACS Chem Biol; 2019 Sep; 14(9):2071-2087. PubMed ID: 31390185
[TBL] [Abstract][Full Text] [Related]
15. Enhancing the Cell Permeability of Stapled Peptides with a Cyclic Cell-Penetrating Peptide.
Dougherty PG; Wen J; Pan X; Koley A; Ren JG; Sahni A; Basu R; Salim H; Appiah Kubi G; Qian Z; Pei D
J Med Chem; 2019 Nov; 62(22):10098-10107. PubMed ID: 31657556
[TBL] [Abstract][Full Text] [Related]
16. Targeting of p53 peptide analogues to anti-apoptotic Bcl-2 family proteins as revealed by NMR spectroscopy.
Shin JS; Ha JH; Chi SW
Biochem Biophys Res Commun; 2014 Jan; 443(3):882-7. PubMed ID: 24342622
[TBL] [Abstract][Full Text] [Related]
17. Peptide-based inhibitors of protein-protein interactions.
Wójcik P; Berlicki Ł
Bioorg Med Chem Lett; 2016 Feb; 26(3):707-713. PubMed ID: 26764190
[TBL] [Abstract][Full Text] [Related]
18. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
19. Targeting the MDM2/MDM4 interaction interface as a promising approach for p53 reactivation therapy.
Pellegrino M; Mancini F; Lucà R; Coletti A; Giacchè N; Manni I; Arisi I; Florenzano F; Teveroni E; Buttarelli M; Fici L; Brandi R; Bruno T; Fanciulli M; D'Onofrio M; Piaggio G; Pellicciari R; Pontecorvi A; Marine JC; Macchiarulo A; Moretti F
Cancer Res; 2015 Nov; 75(21):4560-72. PubMed ID: 26359458
[TBL] [Abstract][Full Text] [Related]
20. Rational Design of Right-Handed Heterogeneous Peptidomimetics as Inhibitors of Protein-Protein Interactions.
Shi Y; Sang P; Lu J; Higbee P; Chen L; Yang L; Odom T; Daughdrill G; Chen J; Cai J
J Med Chem; 2020 Nov; 63(21):13187-13196. PubMed ID: 33140956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
